Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
7.57
+0.02 (0.26%)
Feb 4, 2026, 3:04 PM CST
SHE:002581 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | -220.75 | -137.31 | -332.46 | -14.68 | 271 | -195.93 |
Depreciation & Amortization | 41.67 | 41.67 | 70.63 | 74.86 | 65.9 | 59.68 |
Other Amortization | 1.09 | 1.09 | 4.41 | 2.59 | 3.55 | 3.99 |
Loss (Gain) From Sale of Assets | -1.16 | -1.16 | 6.33 | -0.05 | 0.15 | 22.69 |
Asset Writedown & Restructuring Costs | 69.64 | 69.64 | 293.88 | 13.61 | 0.48 | 27.02 |
Loss (Gain) From Sale of Investments | -44.08 | -44.08 | -172.68 | -217.45 | -471.94 | -109.61 |
Provision & Write-off of Bad Debts | -4.73 | -4.73 | -27.56 | -3.48 | -2.2 | 12.05 |
Other Operating Activities | -88.37 | 10.02 | 39.07 | 22.87 | 21.01 | 27.1 |
Change in Accounts Receivable | 67.81 | 67.81 | 69.76 | 2.45 | 75.08 | 106.23 |
Change in Inventory | -9.34 | -9.34 | -15.16 | -16.13 | 6.53 | -4.38 |
Change in Accounts Payable | 11.35 | 11.35 | 6.24 | 68.51 | -15.39 | 73.25 |
Change in Other Net Operating Assets | -8.31 | -8.31 | 15.5 | - | - | - |
Operating Cash Flow | -188.38 | -6.55 | -36.51 | -54.49 | -46.02 | 18.51 |
Operating Cash Flow Growth | - | - | - | - | - | -61.77% |
Capital Expenditures | -109.6 | -9.01 | -4.32 | -31.46 | -60.85 | -67.7 |
Sale of Property, Plant & Equipment | -16.71 | 8.17 | 4.77 | 24.45 | 0.02 | 46.08 |
Divestitures | 73.75 | 73.75 | - | - | - | 0.23 |
Investment in Securities | - | - | 0.03 | -28 | 5 | 14.49 |
Other Investing Activities | 164.51 | 294.16 | 256.17 | -3.4 | - | - |
Investing Cash Flow | 111.95 | 367.06 | 256.65 | -38.42 | -55.83 | -6.9 |
Short-Term Debt Issued | - | - | - | 227.5 | 218 | 158.5 |
Long-Term Debt Issued | - | 2.77 | 13.84 | 62.95 | - | - |
Total Debt Issued | 10.77 | 2.77 | 13.84 | 290.45 | 218 | 158.5 |
Short-Term Debt Repaid | - | - | - | -229 | -188 | -875.12 |
Long-Term Debt Repaid | - | -10.56 | -214.7 | -13.39 | -25.3 | -23.18 |
Total Debt Repaid | -10.39 | -10.56 | -214.7 | -242.39 | -213.3 | -898.3 |
Net Debt Issued (Repaid) | 0.38 | -7.79 | -200.87 | 48.06 | 4.7 | -739.8 |
Common Dividends Paid | -0.57 | -0.18 | -10.28 | -8.04 | -6.71 | -55.35 |
Other Financing Activities | -0.64 | - | - | 7.88 | 7.49 | 6.7 |
Financing Cash Flow | -0.83 | -7.97 | -211.14 | 47.89 | 5.49 | -788.45 |
Foreign Exchange Rate Adjustments | -0 | 0 | -0 | 0 | -0 | 0.01 |
Net Cash Flow | -77.26 | 352.54 | 9 | -45 | -96.35 | -776.83 |
Free Cash Flow | -297.97 | -15.56 | -40.82 | -85.95 | -106.86 | -49.19 |
Free Cash Flow Margin | -115.61% | -4.32% | -9.50% | -24.07% | -26.53% | -17.77% |
Free Cash Flow Per Share | -0.45 | -0.02 | -0.06 | -0.13 | -0.16 | -0.07 |
Cash Income Tax Paid | 16.87 | 22.6 | 31.75 | 15.49 | 20.31 | 19.81 |
Levered Free Cash Flow | -300.41 | 32.36 | -107.84 | 85.69 | 1.83 | -6.45 |
Unlevered Free Cash Flow | -300.28 | 32.49 | -102.18 | 91.57 | 6.13 | 9.44 |
Change in Working Capital | 58.32 | 58.32 | 81.88 | 67.26 | 66.03 | 171.52 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.